← Back to Search

Biofeedback + Injection for Bowel Incontinence

Saint Paul, MN
N/A
Waitlist Available
Led By William Whitehead, PhD
Research Sponsored by Mayo Clinic
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Less than 75% reduction in the number of FI episodes after 4 weeks of conservative treatment
Age 18 years or older
Must not have
History of pelvic radiation within the previous 12 months or presence of active radiation proctitis
Patients with Parkinson's disease, multiple sclerosis, severe diabetic neuropathy documented by electromyography (EMG), and neurodegenerative disorder
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 24 months
Awards & highlights
No Placebo-Only Group

Summary

This trial is for patients with severe fecal incontinence who haven't responded to initial treatments. It compares two methods: muscle training and a treatment that adds bulk to the rectum. The goal is to see which method better reduces incontinence episodes.

See full description
Who is the study for?
Adults with severe fecal incontinence, experiencing more than two episodes per week despite 4 weeks of conservative treatment. Participants must be able to walk independently and have had a physician's diagnosis for at least six months. Exclusions include significant anal pain or injuries, certain anatomic limitations, allergies to specific products, pregnancy plans within two years, and various medical conditions like inflammatory bowel disease or neurological disorders.Check my eligibility
What is being tested?
The FIT Study is testing the effectiveness of Biofeedback versus Injection of Solesta after initial Enhanced Medical Management fails to reduce fecal incontinence by 75%. Patients who don't improve sufficiently will be randomized into one of these treatments and followed up for efficacy, safety, and cost over a total period of 24 months.See study design
What are the potential side effects?
Potential side effects may include discomfort at the injection site for those receiving Solesta injections or muscle strain from biofeedback exercises. There could also be risks associated with not responding to treatment leading to continued episodes of incontinence.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My conservative treatment for FI didn't reduce episodes by 75% after 4 weeks.
 show original
Select...
I am 18 years old or older.
 show original

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have had pelvic radiation in the last year or have active inflammation of the rectum due to radiation.
 show original
Select...
I have Parkinson's, multiple sclerosis, severe diabetic neuropathy, or a neurodegenerative disorder.
 show original
Select...
I have experienced significant pain in my anal area in the last 6 months.
 show original
Select...
I have had specific pelvic or anal surgeries or issues with synthetic grafts recently.
 show original
Select...
I do not have 4 or more very loose bowel movements per day for 4 or more days a week.
 show original
Select...
My imaging tests show a significant separation in my internal anal sphincter.
 show original
Select...
I have a spinal cord injury or spina bifida.
 show original
Select...
I have not had serious anal or rectal problems in the last 6 months.
 show original
Select...
I have an intestinal stoma.
 show original
Select...
I have been diagnosed with inflammatory bowel disease.
 show original
Select...
I am currently on immunotherapy or chemotherapy.
 show original
Select...
I have severe rectal prolapse or advanced hemorrhoids.
 show original
Select...
I am willing to stop taking unapproved medications or supplements that affect my stool consistency for the study.
 show original

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 24 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 24 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Proportion of Participants with Specified Adverse Events at Month 3 Follow-Up
Treatment Costs at Month 3 Follow-Up
Treatment Response Defined as a 75% or Greater Change in Number of Average Weekly FI Episodes at Month 3 Follow-Up Compared to Baseline
Secondary study objectives
Change in Psychological Distress as Assessed Using the 7-item Patient-Reported Outcomes Measurement Information System (PROMIS) Anxiety Scale
Change in Psychological Distress as Assessed Using the 8-item PROMIS Depression Scale
Change in Psychological Distress as Assessed Using the 8-item PROMIS Self-Efficacy Symptom Management Scale
+4 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Active Control
Group I: Biofeedback (BIO)Active Control1 Intervention
Participants will receive biofeedback intervention during five (5) required weekly 1-hour sessions. A 6th treatment session will be made available for participants if it is shown through anorectal manometry that they are having trouble understanding directions given during the first five sessions.
Group II: Injection (INJ)Active Control1 Intervention
Bulking agent injected into rectal wall to narrow opening. Two visits each lasting 45 minutes at weeks 0 and 6 respectively.

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Biofeedback and the injection of bulking agents like Solesta are common treatments for bowel incontinence. Biofeedback focuses on training and strengthening the pelvic floor muscles, improving muscle control and coordination to reduce incontinence episodes. The injection of bulking agents such as Solesta adds volume to the anal sphincter, enhancing its ability to close more effectively and prevent leakage. These treatments are crucial for bowel incontinence patients as they address the underlying muscle and structural issues, providing non-surgical options to improve their quality of life.
[Biofeedback in faecal incontinence].

Find a Location

Closest Location:Colon and Rectal Surgery Associates, Ltd.· Saint Paul, MN

Who is running the clinical trial?

University of MichiganOTHER
1,887 Previous Clinical Trials
6,462,092 Total Patients Enrolled
University of Alabama at BirminghamOTHER
1,673 Previous Clinical Trials
2,456,936 Total Patients Enrolled
RTI InternationalOTHER
200 Previous Clinical Trials
941,542 Total Patients Enrolled
University of North Carolina, Chapel HillOTHER
1,584 Previous Clinical Trials
4,363,478 Total Patients Enrolled
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NIH
2,500 Previous Clinical Trials
4,353,720 Total Patients Enrolled
Mayo ClinicLead Sponsor
3,413 Previous Clinical Trials
3,208,552 Total Patients Enrolled
Colon and Rectal Surgery Associates, Ltd.OTHER
2 Previous Clinical Trials
224 Total Patients Enrolled
Augusta UniversityOTHER
218 Previous Clinical Trials
85,655 Total Patients Enrolled
William Whitehead, PhDPrincipal InvestigatorUniversity of North Carolina, Chapel Hill
Adil Bharucha, MDPrincipal InvestigatorMayo Clinic

Media Library

Biofeedback Clinical Trial Eligibility Overview. Trial Name: NCT03811821 — N/A
Bowel Incontinence Research Study Groups: Biofeedback (BIO), Injection (INJ)
Bowel Incontinence Clinical Trial 2023: Biofeedback Highlights & Side Effects. Trial Name: NCT03811821 — N/A
Biofeedback 2023 Treatment Timeline for Medical Study. Trial Name: NCT03811821 — N/A
~38 spots leftby Mar 2026